ArticleFrontiers in cellular and infection microbiology2025
Studies on the antibacterial activity of the antimicrobial peptide Mastoparan X against methicillin-resistant
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Lauric Acid Microemulsions InhibitFoods (Basel, Switzerland) · 2026Article
- Antimicrobial, antibiofilm, and virulence gene modulatory effects of supercritical CO₂ extracts of Thymbra spicata against clinical MRSA isolates.Folia microbiologica · 2026Article
- Arginine-substituted Mastoparan-C derivatives combat dual bacterial pathogens:Microbiology spectrum · 2026Article
- Novel lipid and ascorbyl stearate biomimetic vancomycin-loaded nanostructured lipid carrier therapy for bacterial infections and sepsis.RSC advances · 2026Article
- Bioactive Silver Nanoparticles Synthesized Using EndophyticPharmaceuticals (Basel, Switzerland) · 2026Article
- Enhancing ε-poly-L-lysine production in Streptomyces albulus through tea polyphenols addition.Bioprocess and biosystems engineering · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Antimicrobial peptides: natural templates for next-generation therapeutics against antimicrobial resistance.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methicillin-resistant Methods: Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of Mastoparan X against MRSA USA300 were determined by microbroth dilution method. The antibacterial activity of Mastoparan X against USA300 was then evaluated by time-growth curves, membrane fluidity, reactive oxygen species(ROS), flow cytometry, scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM). In addition, the inhibitory and scavenging effects of Mastoparan X on USA300 biofilm were evaluated using crystal violet staining. Finally, gene expression changes in USA300 after treatment with Mastoparan X were analyzed by transcriptomics and verified by RT-qPCR. Results: The MIC and MBC of Mastoparan X on USA300 were 32 μg/mL and 64 μg/mL, respectively. SEM observation showed significant changes in cell morphology after Mastoparan X treatment. Flow cytometry confirmed that Mastoparan X promoted the apoptosis of MRSA cells. In addition, Mastoparan X inhibited the formation of MRSA biofilm while destroying the mature bioepithelia already formed. Transcriptomic analysis showed that 851 genes were significantly altered and ABC transport protein, amino acid biosynthesis, glycolysis and tricarboxylic acid (TCA) cycle were inhibited after 16μg/mL Mastoparan X treatment. Conclusion: Our study demonstrated that Mastoparan X has potent bactericidal activity against MRSA and is expected to provide new potential peptides for the clinical treatment of MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.